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Abstract
In severe cases of  sarcoidosis treatment can be very
difficult. The common treatment strategies might be
failing. Tumour necrosis factor (TNF) α therapy is ap-
proved in rheumatoid arthritis, M. Crohn, psoriasis and
ankylosing spondylitis. In sarcoidosis more recently a
phase 2, multicenter, randomized, double-blind,
placebo-controlled study was conducted in 138 patients
with chronic sarcoidosis with pulmonary involvement.
Patients in the combined infliximab groups (3 and 5
mg/kg) had a statistically significant improvement of
the FVC (mean increase of  2.5% from baseline to week
Introduction
Sarcoidosis is an antigen-driven, multisystem,
granulomatous disorder, the cause of  which
is not known. In a genetically susceptible in-
dividual, antigen-presenting cells trap, proc-
ess, and present the putative antigen, in the
context of class II major histocompatibility
complex (MHC) molecules, to CD4+ lym-
phocytes. The result of  this union is a coor-
dinated release of  cytokines and chemokines,
which recruit more inflammatory cells (lym-
phocytes, mononuclear phagocytes, and
fibroblasts) and mount a granulomatous re-
sponse dominated by interferon-γ and inter-
leukin-12. Although the exact etiology re-
mains unknown, current evidence supports
24 in the percent of  predicted FVC, compared with no
change in placebo-treated patients (p=0.038)). Studies
in the earlier mentioned diseases revealed that inade-
quate treatment responses could result from incomplete
suppression of  TNF α activity. This suggests that in-
creasing patients’ dose or frequency of  infliximab could
in turn improve their clinical response. Further evalua-
tion of anti-TNF therapy in symptomatic patients with
severe, chronic sarcoidosis is needed.
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the concept that the pathogenesis of  sar-
coidosis involves a highly polarized T-helper
1 (Th1) immune response to pathogenic tis-
sue antigens or specific environmental fac-
tors. Granuloma formation is regulated by a
complex interaction between T-helper lym-
phocytes and macrophages, in which cy-
tokines such as tumour necrosis factor
(TNF)-α play an important role (Fig. 1). In a
small number of  patients, profibrotic cy-
tokines, including transforming growth
factor-β and TNF-α, appear and move the
inflammatory process towards fibrosis.1,2
Treatment
The recommended treatments for sarcoido-
sis differ from none to a combination of
cytotoxic agents. A major reason for this wide
spectrum of  treatment relates to the varia-
tion in disease presentation. The use of  sys-
temic therapy for sarcoidosis is usually driv-
en by symptoms. There are several efficacious
agents for the treatment of  sarcoidosis (Ta-
ble I)3. The common mechanism for action
of  these drugs is their effect on the immune
response, especially the suppression of  tu-
mour necrosis factor (TNF), a key cytokine
in chronic sarcoidosis1. The absolute need for
systemic therapy include manifestations
which are life or organ threatening. In long
term studies analyzing mortality from sar-
coidosis, the most common causes of  death
are pulmonary, cardiac, neurologic, and he-
patic1. For respiratory impairment, a low vi-
tal capacity is a relative indicator of  increased
mortality. Moreover, treatment options vary
because no treatment is a cure of the dis-
ease, but actually just a means to control
symptoms1-3. Conventional treatment is fo-
cused on attenuating granuloma formation
with antimalarial drugs that inhibit antigen
presentation or with non specific anti-
-inflammatory agents such as glucocorticos-
teroids, methotrexate, or azathioprine. Anti-
-TNF-α agents such as Infliximab and
thalidomide have recently shown some suc-
cess in sarcoidosis (see also chapter R.P.
Baughman)4-7. The design of  future thera-
pies depends, among others on the improved
knowledge of  the critical immunological
processes operative in different stages of
disease.
Infliximab
The anti-TNF-α agent infliximab (Remi-
cade®) is a recombinant immunoglobulin G1-
-κ (IgG1-κ) human-murine chimeric mono-
clonal antibody that specifically and potently
binds and neutralizes the soluble TNF-α
homotrimer and its membrane bound pre-
cursor. The high-affinity binding prevents the
interaction of  TNF-α with its cellular recep-
tors, attenuating inflammatory and other
deleterious effects related to TNF overpro-
duction8. Many case reports are published il-
lustrating the efficacy of  Infliximab. Favour-
able results are also found in patients treated
in our hospital (see also Figures 3 and 4)9.
To assess the efficacy of  infliximab in sar-
coidosis a phase 2, multicenter, randomized,
double-blind, placebo-controlled study was
conducted in 138 patients with chronic sar-
coidosis with pulmonary involvement6. Pa-
tients were randomized to receive intrave-
nous infusions of  infliximab (3 or 5 mg/kg)
or placebo at weeks 0, 2, 6, 12, 18, and 24
and were then followed through week 52.
The primary endpoint was the change from
baseline to week 24 in percent of  predicted
forced vital capacity (FVC). Patients in the
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Fig. 1 – Hypothetical model of the pathogenesis of sarcoidosis. An inciting agent induces antigen-specific, Th1-
-mediated granulomatous inflammation with production of Th1 cytokines such as interferon (IFN)-γ and interleukin
(IL)-2. Macrophages, activated directly by the inciting agent and by IFNγ, produce IL-12, TNF-α, IL-6 and other
cytokines important in cell activation, proliferation and recruitment. Activated macrophages and T-cells along with
other effector cells such as fibroblasts, orchestrate the complex process of granuloma formation under the regulatory
influence of local cytokine production. Removal of inciting agent allows immunosuppressive cytokines such as
tumour growth factor (TGF)-β to down regulate the immune response with return to cytokine homeostasis. Granuloma
regression likely occurs by cell apoptosis. Persistent antigenic stimulation results in cytokine dysregulation and
possibly, T-cell autoimmune responses. If untreated, chronic antigenic stimulation and cytokine production results
in tissue injury which, together with up regulated production of TGF-β and other profibrotic cytokines, lead to
irreversible fibrosis (adapted from Moller).2
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combined infliximab groups (3 and 5 mg/
kg) had a statistically significant improvement
of  the FVC (mean increase of  2.5% from
baseline to week 24 in the percent of  pre-
dicted FVC, compared with no change in
placebo-treated patients (p=0.038, see Fig.
2)). Results of  post hoc exploratory analyses
suggested that patients with more severe dis-
ease tended to benefit more from infliximab
treatment. No significant differences be-
tween the treatment groups were observed
for any of  the major secondary endpoints at
week 24. Further evaluation of  anti-TNF
therapy in symptomatic patients with severe,
chronic sarcoidosis is needed.
Table I – Drug therapy for sarcoidosis3
Class Drug Dose Comments
Corticosteroids Prednisone 5-40 mg Initial dose higher, reduce to minimal
tolerable and effective dose
Prednisolone 5-40 mg
Budesonide 800-1600 ugm Inhaled therapy
Triamcinolone Used in topical therapy for skin
Cytotoxic Methotrexate (MTX) 5-15 mg once a week Takes up to 6 month to be effective
with folic acid 5mg once a week
Azathioprine 50-250 mg daily More leukopenic than MTX
Chlorambucil 2-12 mg daily Higher rate of malignancy than other agents
Leflunomide 10-20 mg daily Similar to MTX, but less nausea
Cyclophosphamide 50-150 mg oral daily OR Higher rate of side effects, but associated
500-2000 mg intravenously with higher response rate than
every 2 weeks other cytotoxic agents
Anti-microbial agents Chloroquine
Hydroxychloroquine 200-400 mg daily Less ocular toxicity than chloroquine
Minocycline 100-200 mg daily Rarely associated with immune toxicity
Cytokine modulation Pentoxifylline 200-400 up to three times a day High doses may be needed to block TNF.
Thalidomide 50-200 mg daily Teratogenic potential major concern
Infliximab 5 mg/kg intravenously every Increase rate of infection and allergic reaction
4-8 weeks after loading doses
Experience from other studies
Recent clinical experience in rheumatoid arthri-
tis (RA) patients who are being treated with
intermittent (every 8 weeks) pulse Infliximab
therapy indicates that in some patients the dis-
ease flares a few days or weeks before their
next pulse therapy10. This was recently found
to correlate with the serum levels of  inflixi-
mab. Inadequate suppression of  serum TNF-
-α level after infliximab infusion in RA patients
with active disease was demonstrated11. RA
patients with active disease had significantly
higher levels of  serum TNF- which could not
be suppressed by infliximab. Therefore, it was
hypothesized that inadequate treatment re-
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sponses could result from incomplete suppres-
sion of  TNF a activity. This suggests that in-
creasing patients’ dose or frequency of  inflixi-
mab could in turn improve their clinical
response11. For patients with inadequate re-
sponse, dose per infusion can be increased to
as much as 10 mg/kg, or the frequency of  in-
fusions can be increased to once every 4 weeks.
Fig. 2 – Primary endpoint, change from baseline in percentage predicted FVC at week 24.6
Fig. 3 – HRCT features of a patient with severe sarcoidosis not responding to the conventional therapy. Left: before
treatment with Infliximab, right: after 6 months treatment with Infliximab. There is a substantial improvement of the micro
nodular lesions and the consolidation9.
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There is growing evidence that substantial num-
bers of  patients who receive infliximab have
their dose and/or frequency of infusions in-
creased12. Many patients with RA who receive
infliximab experience dose intensification with-
in the first year of  therapy. Moreover, analysis
of  data from ATTRACT, a placebo-controlled
double-blind, randomized clinical trial of inf-
liximab in patients with active RA refractory to
MTX treatment, showed that clinical improve-
ment of RA is dose-related and that higher
trough levels of  infliximab may be beneficial
for patients with RA10. Whether this theory
holds true in clinical practice and whether to
increase the infusion dose or the frequency of
their infusions are questions that remain unan-
swered. This applies similarly to other autoim-
mune and inflammatory disorders in which
TNF-α plays an important role, such as anky-
losing spondylitis (AS), psoriasis and
sarcoidosis13-15. Also, the concomitant use of
immunosuppressive agents like methotrexate
or azathioprine in order to reduce immuno-
genicity and increase the long-term efficacy of
infliximab has to be further investigated16.
Conclusion
It is tempting to speculate that in sarcoido-
sis a reduction of  the time between infusions
may reveal greater therapeutic benefit, but
this remains to be proven. Moreover, it re-
mains to be seen if  serum TNF-α levels
could be used as guide in determining the
dose and intervals between dosing of  anti-
-TNF therapy in order to achieve the desired
clinical response. If  true, this may indicate
what many providers believe that the recom-
mended initial dose of  infliximab is too low,
a belief  supported by the need for dose es-
calation in many patients. This underlines the
need for future studies to explore the real
benefit for severe sarcoidosis patients of
appropriate anti-TNF therapy.
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Fig. 4 – Right eye of a sarcoidosis patient with macular edema (arrow); before treatment (left) and after treatment with
infliximab (right).
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